Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Introduction: Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in patients with T2-driven inflammatory diseases. However,...

Full description

Bibliographic Details

Published in:	Frontiers in pharmacology Vol. 14; p. 1276340
Main Authors:	Pera, Victor, Brusselle, Guy G., Riemann, Sebastian, Kors, Jan A., Van Mulligen, Erik M., Parry, Rowan, de Wilde, Marcel, Rijnbeek, Peter R., Verhamme, Katia M. C.
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 14.11.2023
Subjects:	biologicals disproportionality analysis FAERS monoclonal antibodies parasitic infections Pharmacology spontaneous reporting
ISSN:	1663-9812, 1663-9812
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!